Skip to content

T · 4519.T · DRUG MANUFACTURERS - GENERAL

Chugai Pharmaceutical Co., Ltd. (4519.T) intrinsic value and stock valuation

$7,109.00as of 2026-11-21 · Mkt cap 12.77T

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Chugai Pharmaceutical Co., Ltd. DCF and intrinsic value

InvestorsCraft values 4519.T with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 4519.T’s statements →

Chugai Pharmaceutical Co., Ltd. Graham Number

Graham Number: $2,702.67d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - General Tokyo 103-8324 chugai-pharm.co.jp

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.26T+9.8% 5y CAGRd
20112025
Net income
$434B+15.1% 5y CAGRd
20112025
Free cash flow
$313.2B+16.9% 5y CAGRd
20112025
Total equity
$2.03T+15.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.26T$1.17T$1.11T$1.26T$999.8B
Operating income$590.2B$543.9B$415.7B$533.9B$433.7B
Net income$434B$387.3B$325.5B$374.4B$303B
EPSd$263.7M$235.4M$197.8M$227.6M$184.2M
Operating cash flow$389.5B$447.6B$409.9B$244.1B$279.6B
Capital expenditure-$-76.27B-$-50.93B-$-74.26B-$-71.24B-$-72.87B
Free cash flow$313.2B$396.7B$335.7B$172.9B$206.8B
Total assets$2.47T$2.21T$1.93T$1.87T$1.54T
Total debt$0.00$10.9B$13.5B$14.1B$16B
Net debt-$-426.6B-$-529.31B-$-445.22B-$-208.06B-$-251.71B
Total equity$2.03T$1.9T$1.63T$1.42T$1.19T
Cash and short-term investments$979.7B$996.3B$739B$503.1B$472B
Income statement
20252024202320222021
Revenue$1.26T$1.17T$1.11T$1.26T$999.8B
Cost of revenue$363.7B$339.9B$418.4B$476.9B$339.5B
Gross profit$894.3B$830.7B$693B$783.1B$660.3B
Research and development expenses$187.6B$176.7B$164.8B$148.4B$131.3B
Selling, general and administrative expenses$116.5B$110.1B$112.6B$100.8B$95.3B
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$304.1B$286.8B$277.3B$249.1B$226.5B
Cost and expenses$667.7B$626.7B$695.7B$726B$566B
Interest income$3.6B$2.67B$1.78B$182M$166M
Interest expense$1.03B$95M$82M$60M$49M
Depreciation and amortization$32.5B$31.7B$31.7B$31.4B$30.9B
Ebitda$631.4B$574.8B$475.6B$562.7B$450.3B
Operating income$590.2B$543.9B$415.7B$533.9B$433.7B
Total other income/expenses, net$7.62B-$-873M$28.2B-$-2.78B-$-14.35B
Income before tax$597.8B$543B$443.8B$531.2B$419.4B
Income tax expense$163.8B$155.7B$118.3B$156.7B$116.4B
Net income$434B$387.3B$325.5B$374.4B$303B
Weighted average shares outstanding$1.65B$1.65B$1.65B$1.64B$1.64B
Weighted average diluted shares outstanding$1.65B$1.65B$1.65B$1.65B$1.65B
Balance sheet
20252024202320222021
Cash and short-term investments$979.7B$996.3B$739B$503.1B$472B
Net receivables$443.1B$334.3B$318.9B$512.5B$356B
Inventory$276.8B$240.1B$273.5B$292.2B$208.8B
Total current assets$1.74T$1.61T$1.37T$1.34T$1.06T
Property, plant and equipment, net$479.5B$441.6B$420.7B$386.7B$352.1B
Goodwill and intangible assets$54.5B$17.9B$19.9B$25.1B$22B
Long-term investments$0.00$3.91B$1.25B-$-279.1B-$-201.82B
Total non-current assets$727.8B$602.3B$566.1B$533.2B$475B
Total assets$2.47T$2.21T$1.93T$1.87T$1.54T
Accounts payable$127.2B$16.1B$54.2B$144.1B$97.2B
Short-term debt$0.00$6.37B$6.98B$6.43B$6.55B
Deferred revenue$0.00$31M$31M$79M$86M
Total current liabilities$411.1B$290.4B$288.2B$423.7B$327.4B
Long-term debt$0.00$4.53B$6.48B$7.68B$9.49B
Deferred revenue, non-current$0.00$396M$378M$430M$490M
Total non-current liabilities$31.8B$16.5B$18.7B$21.6B$23.3B
Capital lease obligations$0.00$4.53B$6.48B$7.68B$9.49B
Total liabilities$442.9B$306.9B$307B$445.4B$350.7B
Common stock$73.2B$73.2B$73.2B$73.2B$73.2B
Retained earnings$1.89T$1.75T$1.49T$1.29T$1.05T
Accumulated other comprehensive income (loss)-$-8.03B$11.5B-$-5.72B-$-10.97B-$-7.46B
Total equity$2.03T$1.9T$1.63T$1.42T$1.19T
Total investments$553.1B$460.1B$281.6B$1.84B$2.39B
Total debt$0.00$10.9B$13.5B$14.1B$16B
Net debt-$-426.6B-$-529.31B-$-445.22B-$-208.06B-$-251.71B
Cash flow statement
20252024202320222021
Net income$434B$387.3B$325.5B$575.9B$470.4B
Depreciation and amortization$32.5B$31.7B$31.7B$31.4B$30.9B
Stock-based compensation$0.00$383M$0.00$0.00$0.00
Change in working capital-$-79.65B-$-28.84B$130.6B-$-183.31B-$-83.12B
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities$389.5B$447.6B$409.9B$244.1B$279.6B
Investments in property, plant and equipment-$-111.61B-$-50.93B-$-71.95B-$-71.24B-$-72.87B
Acquisitions, net$7.51B$0.00$0.00$1.05B$6.9B
Net cash used for investing activities-$-204.87B-$-227.37B-$-37.29B-$-145.99B-$-118.93B
Common stock issued$142M$168M$217M$241M$322M
Common stock repurchased-$-6M-$-10M-$-5M-$-5M-$-8M
Dividends paid-$-299.42B-$-133.25B-$-131.59B-$-138.22B-$-98.64B
Net cash used for financing activities-$-307.46B-$-141.01B-$-139.33B-$-145.64B-$-107.41B
Net change in cash-$-113.6B$81.5B$236.5B-$-45.58B$55.4B
Cash at end of period$426.6B$540.2B$458.7B$222.2B$267.8B
Operating cash flow$389.5B$447.6B$409.9B$244.1B$279.6B
Capital expenditure-$-76.27B-$-50.93B-$-74.26B-$-71.24B-$-72.87B
Free cash flow$313.2B$396.7B$335.7B$172.9B$206.8B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Chugai Pharmaceutical Co., Ltd.

        Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

        CEO
        Osamu Okuda
        Employees
        5.03K
        Beta
        0.56

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Chugai Pharmaceutical Co., Ltd. (4519.T)?

        InvestorsCraft does not currently publish an intrinsic value for 4519.T. How the IC value is calculated.

        Is 4519.T undervalued?

        InvestorsCraft does not publish an undervaluation signal for 4519.T at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.